Last updated on August 2019

Watchman FLX Left Atrial Appendage Closure Device Post Approval Study ( Europe Only)


Brief description of study

Watchman FLX Left Atrial Appendage Closure Device Post Approval Study

Detailed Study Description

WATCHMAN FLX is intended to prevent thrombus embolization from the left atrial appendage and reduce the risk of life-threatening bleeding events in patients with non-valvular atrial fibrillation who are eligible for anticoagulation therapy or who have a contraindication to anticoagulation therapy.

Clinical Study Identifier: NCT02654470

Find a site near you

Start Over